Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,410
Employees15,410
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,410
Employees15,410

REGN Key Statistics

Market cap
64.37B
Market cap64.37B
Price-Earnings ratio
14.98
Price-Earnings ratio14.98
Dividend yield
0.58%
Dividend yield0.58%
Average volume
1.47M
Average volume1.47M
High today
$624.47
High today$624.47
Low today
$609.77
Low today$609.77
Open price
$620.11
Open price$620.11
Volume
2.19M
Volume2.19M
52 Week high
$821.11
52 Week high$821.11
52 Week low
$476.49
52 Week low$476.49

Stock Snapshot

With a market cap of 64.37B, Regeneron(REGN) trades at $615.02. The stock has a price-to-earnings ratio of 14.98 and currently yields dividends of 58.2%.

As of 2026-05-31, Regeneron(REGN) stock has fluctuated between $609.77 and $624.47. The current price stands at $615.02, placing the stock +0.9% above today's low and -1.5% off the high.

Regeneron(REGN) shares are trading with a volume of 2.19M, against a daily average of 1.47M.

In the last year, Regeneron(REGN) shares hit a 52-week high of $821.11 and a 52-week low of $476.49.

In the last year, Regeneron(REGN) shares hit a 52-week high of $821.11 and a 52-week low of $476.49.

REGN News

Simply Wall St 19h
WHO Ebola Trial Puts Regeneron’s Maftivimab Platform In Investor Focus - simplywall.st

...

WHO Ebola Trial Puts Regeneron’s Maftivimab Platform In Investor Focus - simplywall.st
TipRanks 2d
Regeneron Steps Into CAR T for Advanced Prostate Cancer With New Phase 1 Trial

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from a...

TipRanks 2d
Regeneron Expands Into Pulmonary Hypertension With New Phase 2 Trial for REGN13335

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from a...

Analyst ratings

74%

of 31 ratings
Buy
74.2%
Hold
25.8%
Sell
0%

More REGN News

TipRanks 2d
Regeneron Targets Stroke Prevention Gap With New Atrial Fibrillation Trial

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from a...

TipRanks 3d
Regeneron Ebola antibody recommended by WHO for investigational use

Regeneron (REGN) announced that maftivimab, the most potent neutralizing antibody included in Inmazeb, has been recommended by the World Health Organization’s,...

Investor's Business Daily 4d
Why Apogee Slipped On Its Dupixent-Rivaling Eczema Results

Technology Why Apogee Slipped On Its Dupixent-Rivaling Eczema Results Licensing Apogee Therapeutics (APGE) reported mixed results for its experimental eczema tr...

Why Apogee Slipped On Its Dupixent-Rivaling Eczema Results
Simply Wall St 6d
A Look At Regeneron Pharmaceuticals Valuation After Recent Trial Wins And New Research Partnership

Regeneron Pharmaceuticals (REGN) is back in focus after three pipeline updates in quick succession, including early Lynozyfic data in systemic AL amyloidosis, a...

A Look At Regeneron Pharmaceuticals Valuation After Recent Trial Wins And New Research Partnership

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.